Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 9/20 | 0.57 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | DHFR | P00374 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | ECE2 | P0DPD6 | 1/20 | 0.41 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4639694 | 1.00 | BACE1 (0.57) | BACE1BRD4DHFRCYP19A1MAOA | |
| SCHEMBL4640096 | 1.00 | BACE1 (0.57) | BACE1BRD4DHFRCYP19A1MAOA | |
| SCHEMBL4639688 | 0.78 | BACE1 (0.52) | BACE1MAOBADORA2AMEN1KMT2A | |
| SCHEMBL4639689 | 0.78 | BACE1 (0.52) | BACE1MAOBADORA2AMEN1KMT2A | |
| SCHEMBL4639823 | 0.78 | BACE1 (0.52) | BACE1MAOBADORA2AMEN1KMT2A | |
| SCHEMBL4149461 | 0.78 | BACE1 (0.71) | BACE1BRD4MEN1KMT2A | |
| SCHEMBL4136351 | 0.76 | BACE1 (0.61) | BACE1CYP19A1MAOAMAOBADORA2A | |
| SCHEMBL4136356 | 0.76 | BACE1 (0.61) | BACE1CYP19A1MAOAMAOBADORA2A | |
| SCHEMBL4512841 | 0.74 | BACE1 (0.72) | BACE1BRD4 | |
| SCHEMBL4134504 | 0.74 | BACE1 (0.81) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080318985-A1 | Novel 2-Aminopyrimidinone Or 2-Aminopyridinone Derivatives and Their Use | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | claimed |
| EP-1951682-A1 | NOVEL 2-AMINOPYRIMIDINONE OR 2-AMINOPYRIDINONE DERIVATIVES AND THEIR USE | Astra Zeneca AB (SE) | 2008-08-06 | — | — | EP | claimed |
| WO-2007058582-A1 | NOVEL 2-AMINOPYRIMIDINONE OR 2-AMINOPYRIDINONE DERIVATIVES AND THEIR USE | ASTRAZENECA AB (SE) | 2007-05-24 | — | — | WO | claimed |
| US-20080318985-A1 | Novel 2-Aminopyrimidinone Or 2-Aminopyridinone Derivatives and Their Use | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| EP-1951682-A1 | NOVEL 2-AMINOPYRIMIDINONE OR 2-AMINOPYRIDINONE DERIVATIVES AND THEIR USE | Astra Zeneca AB (SE) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007058582-A1 | NOVEL 2-AMINOPYRIMIDINONE OR 2-AMINOPYRIDINONE DERIVATIVES AND THEIR USE | ASTRAZENECA AB (SE) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318985-A1 | Novel 2-Aminopyrimidinone Or 2-Aminopyridinone Derivatives and Their Use | PSEN2, PSEN1, GRIN2D | BACE1 12/4885BRD4 1238/4885DHFR 1731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.